AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01159977 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facilitated small groups
Description: 1 hour sessions every 2 weeks for small groups of 9 participants, 19 sessions over 9 months.
Study NCT01159977 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Unstructured time.
Description: 1 protected hour every 2 weeks for 9 months, without small group structure.
Study NCT01159977 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual practice
Description: No protected time provided.
Study NCT04637906 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bioarginina®
Description: Food supplement based on 1,66 grams of L-arginine
Study NCT04637906 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Bioarginina®
Description: Food supplement based on 1,66 grams of L-arginine
Study NCT01703286 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: 1 mg for 7 days followed by uptitration to 2 mg (given for following 21 days)
Study NCT03580577 — intervention group
Intervention type: DEVICE
Intervention: thromboelastography
Description: thromboelastography will assess all coagulation abnormalities including platelets function in cirrhotic group with venous thromboembolism , and guide us about is there increased thrombosis risk or not, for that a fresh blood sample will be withdrawn from each patient before starting any treatment
Study NCT00540722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-(-)-gossypol acetic acid
Description: Given PO
Study NCT00540722 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00755352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pravastatin tablets and Welchol tablets
Description: pravastatin tablets, 1 tablet/day for 6 weeks; Welchol Tablets, 6 tablets/day for 6 weeks
Study NCT00755352 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: pravastatin tablets and Welchol placebo tablets
Description: pravastatin tablets, 1 tablet/day; Welchol placebo tablets, 6 tablets/day
Study NCT01875003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lebrikizumab
Description: Lebrikizumab will be administered as SC injection at high or low dose Q4W.
Study NCT01875003 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lebrikizumab
Description: Lebrikizumab will be administered as SC injection at high or low dose Q4W.
Study NCT01875003 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lebrikizumab matching placebo will be administered as SC injection Q4W.
Study NCT01875003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Participants will continue to receive ICS therapy (total daily dose of 500-2000 mcg fluticasone propionate DPI or equivalent) along with at least one second controller medications (e.g. long-acting beta agonists \[LABAs\], leukotriene receptor antagonists (LTRAs), long-acting muscarinic antagonists (LAMAs), or theophylline) as standard of care.
Study NCT01875003 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Participants will continue to receive ICS therapy (total daily dose of 500-2000 mcg fluticasone propionate DPI or equivalent) along with at least one second controller medications (e.g. long-acting beta agonists \[LABAs\], leukotriene receptor antagonists (LTRAs), long-acting muscarinic antagonists (LAMAs), or theophylline) as standard of care.
Study NCT03793218 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Latera Device
Description: This study seeks to compare a gold standard functional rhinoplasty maneuver, the alar batten graft, to the LATERA implant
Study NCT03793218 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Alar Batten Graft
Description: This study seeks to compare a gold standard functional rhinoplasty maneuver, the alar batten graft, to the LATERA implant
Study NCT02886156 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: CPAP plus BSC group Participants in the CPAP plus BSC group will receive CPAP treatment plus the aforementioned BSC intervention. CPAP treatment (LOTUS AUTO; Curative Medical Technology Inc., Beijing, China) will be initiated using standard clinical practice at each center. Participants in both groups will be asked to continue their usual medical care during the trial.
Study NCT02886156 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: BSC
Description: BSC only group Participants in the BSC only group will receive advice regarding lifestyle modification, sleep hygiene, naps, exercise, caffeine, and diet, and avoiding alcohol consumption, but no specific weight loss program, diet, or salt restriction will be suggested.
Study NCT02886156 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BSC
Description: BSC only group Participants in the BSC only group will receive advice regarding lifestyle modification, sleep hygiene, naps, exercise, caffeine, and diet, and avoiding alcohol consumption, but no specific weight loss program, diet, or salt restriction will be suggested.
Study NCT00715169 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MLN1202
Description: 10 mg/kg dose of MLN1202 administered via IV infusion administered approximately 30 minutes to an hour
Study NCT00715169 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo consist of 0.9% saline solution administered as a 10 mg/kg dose via IV infusion administered approximately 30 minutes to an hour
Study NCT01218282 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home exercise training
Description: 20-30 min/day for at least 4 days/week
Study NCT01218282 — intervention group
Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: NO Exercise Training
Description: No intervention
Study NCT02861131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: At the end of the surgical procedure at a depth of neuromuscular blockade after the reappearance of T2 on the train-of-four, Sugammadex will be dosed once at 2 mg/kg through an intravenous line with brisk flow
Study NCT02861131 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: At the end of surgical procedure at a depth of neuromuscular blockade after the reappearance of T2 on the train-of-four, Neostigmine will be dosed once at 0.07 mg/kg to a maximum of 5 mg through an intravenous line with brisk flow. Glycopyrrolate will be administered with Neostigmine at a dose between 0.1 to 0.2 mg of Glycopyrrolate per 1.0 mg of Neostigmine administered.
Study NCT01684020 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARTISS human fibrin sealant
Study NCT04176887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam Injection
Description: The levetiracetam dose is 20- 40 mg/kg by intravenous infusion over 15 minute, a rate of 2-5 mg/kg/minute diluted in 100 ml with 0.9% sodium chloride as a single dose.
Study NCT03818997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Patient will receive Atezolizumab 840 mg IV every 2 weeks until PD
Study NCT02402192 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corifollitropin alfa
Study NCT02983903 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transbronchial biopsy
Study NCT02456116 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupuncture/PCA/NSAID
Description: standard program with defined points:~1. Ear acupuncture needles bitten once (day 0-5)~2. Body acupuncture, once a day 20 minutes (day -1/ 0/ 2/ 4), depth of the prick 0.5 - 1 cm, with DeQI feeling/sensation is released
Study NCT02456116 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham acupuncture/PCA/NSAID
Description: standard program with defined points:~1. Ear acupuncture needles bitten once (day 0-5)~2. Body acupuncture, once a day 20 minutes (day -1/ 0/ 2/ 4), depth of the prick 0.5
Study NCT04176887 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenytoin Injection
Description: Phenytoin dose is 20-40 mg/kg/min by intravenous infusion over 30 minute, diluted with 0.9% sodium chloride to a maximum concentration of 10 mg/ml.
Study NCT00562744 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulation
Description: Use of high-fidelity patient simulator for training and assessment of PALS scenario performance
Study NCT01244698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefadroxil discontinued early
Description: All patients will receive 24 hours of IV Cefazolin (1g IV every 8 hr), as is universal practice for clean breast surgery. The interventional group will then discontinue antibiotics. Clindamycin IV 600mg every 6 hours for 24 hours will be used in penicillin allergic patients.
Study NCT01244698 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cefadroxil until drain removal
Description: All patients will receive 24 hours of IV Cefazolin, as is universal practice for clean breast surgery. The control group will receive oral outpatient Cefadroxil (500mg 2 times a day) until the final drain is removed. This is the normal postoperative regimen. In case of significant penicillin allergy (defined as a history of urticaria or anaphylaxis associated with penicillin) patients will receive Clindamycin 600mg IV every 6 hours for 24 hours followed by clindamycin 300mg IV every 6 hours.
Study NCT02309866 — intervention group
Intervention type: GENETIC
Intervention: Genetic testing
Description: Genetic testing for mutations in known and novel genes underlying RP and allied diseases
Study NCT03918681 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Intervention
Description: Instruction for all participants in the experimental group will begin with transitioning foot strike pattern from a rearfoot strike to a non-rearfoot strike running pattern (NRFS) and increasing preferred step rate by 5-10%. Each participant program thereafter will be progressed individually according to the clinical investigators follow up assessments of running mechanics and participant pain and function with running. Intervention gait retraining sessions will include drills for reinforcement to include soft landing single leg bounding, adequate time to practice, and pre-class and post-class video assessment with feedback.
Study NCT04437953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avatrombopag
Description: Patients will receive an initial dose of Avatrombopag 60 mg on Day 1. Starting on Day 2, the dose will be Avatrombopag 20 mg daily. Once a patient has reached a platelet target of > 100,000/mcL patients can initiate systemic cancer therapy. Avatrombopag will be continued as maintenance (subscript m) and titrated weekly with a goal to maintain a platelet count of ≥ 100,000/mcL during administration of systemic cancer therapy. Duration of maintenance therapy will be at least 12 weeks (indicated by Week 1m, Week 2m, ... 12m) starting from time of platelet correction and resumption of systemic cancer therapy. End of Treatment (EOT) is up to 15 weeks on study Week 12m.
Study NCT00630474 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: xylometazoline
Description: xylometazoline (0.1 % solution, 3 drops, 0.15 mg) in each nostril
Study NCT00630474 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: xylometazoline
Description: xylometazoline (0.1 % solution, 3 drops, 0.15 mg) in each nostril
Study NCT03210987 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: patient case presentation bedside
Description: Patient case presentation in absence or presence of Patient at bedside.
Study NCT03210987 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: patient case presentation Outside-the-room
Description: Patient case presentation Outside-the-room.
Study NCT01519154 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Only Propofol titrated for induction, followed by Propofol 10 mg/h as maintenance infusion
Study NCT01519154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine-Propofol
Description: Propofol titrated plus additional Ketamine 1 mg/kg at induction, followed by Propofol 10 mg/h as maintenance infusion
Study NCT06400979 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Elequil aromatab
Description: Aromatherapy impregnated tab utilized to dispense inhaled scent for the study
Study NCT04537260 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Video
Description: Those in the intervention arm were asked to watch the 3-minute educational video prior to the knowledge questionnaire and meeting their provider (midwife or obstetrician). The video shown to these participants is linked here: https://youtu.be/Pc9tcIV4Dm8.
Study NCT01236014 — intervention group
Intervention type: DRUG
Intervention: Eltrombopag
Description: Eltrombopag \& standard of care
Study NCT01236014 — intervention group
Intervention type: DRUG
Intervention: Romiplostim
Description: Romiplostim \& standard of care
Study NCT02489045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHAPE measurement (Sonazoid ultrasoud contrast agent)
Description: Three vials with 48 µl of Sonazoid (GE Healthcare, Oslo, Norway) microbubbles (6 ml) will be prepared and drawn into a 10 ml syringe, placed in a syringe pump. Sonazoid will be co-infused at a rate of 0.024 µl/kg body weight/minute (suspension infusion rate of 0.18 ml/kg/hour) together with a 0.9% NaCl solution infused at a rate of at least 2 ml/min.
Study NCT03324412 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment of MTX
Description: Methotrexate: 10-15mg per week according to patient's weight, oral, for 24 weeks.Tripterygium wilfordii Hook F（TwHF）placebo：20mg， 3 times a day, oral, for 24 weeks.
Study NCT01236014 — intervention group
Intervention type: DRUG
Intervention: Placebo
Description: Placebo \& standard of care
Study NCT02670174 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional training
Study NCT02670174 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Separate kinetic chain training
Study NCT02670174 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated kinetic chain training
Study NCT03925168 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music therapy
Description: Music therapy will be administered according to the Eyre (2008) decision tree model. According to this model, the patient chooses his or her preferred musical intervention at the beginning of each session. Choices include: sing songs, compose a song, listen to songs, play instruments, have an imagery experience, listen to music, improvise, and use music for relaxation.
Study NCT02487823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120 in combination with LH-RH agonists (suprefact) and bicalutamide
Description: BKM 120, LH-RH agonists and Bicalutamide
Study NCT03324412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment of MTX and TwHF
Description: Methotrexate : 10-15mg per week according to patient's weight, oral, for 24 weeks.Tripterygium wilfordii Hook F（TwHF）：20mg， 3 times a day, oral, for 24 weeks.
Study NCT03940157 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Oh Happy Day Class - Still I Rise
Description: one-time, 4-hour class focused on awareness of depression and healthy self-management strategies
Study NCT00919360 — intervention group
Intervention type: PROCEDURE
Intervention: collection of maternal blood specimen prior to delivery
Description: approximately 5 cc. of maternal blood will be drawn prior to delivery
Study NCT00919360 — intervention group
Intervention type: PROCEDURE
Intervention: collection of placental cord blood after delivery
Description: approximately 5 cc. of fetal cord blood from the umbilical cord blood vessel will be collected after cord is clamped
Study NCT00919360 — intervention group
Intervention type: PROCEDURE
Intervention: collection of placental tissue
Description: within 10 minutes of delivery, the placenta will be radially transected, and a full-thickness slice from the central region removed using sterile technique by scalpel.This will be placed into a pre-prepared container of RNA preservation medium.
Study NCT00919360 — intervention group
Intervention type: PROCEDURE
Intervention: collection of strip of decidua from uterine lining from cesarean section deliveries
Description: A strip of decidua will be removed from the upper lip of uterine incision by the surgeon and placed in RNA preservation medium.
Study NCT04231019 — intervention group
Intervention type: OTHER
Intervention: self-administered questionnaire
Description: Self-administered questionnaires with plain language statements and brief description of the clinical features and photographs of MIH were used to determine the knowledge, awareness and perception regarding the prevalence, severity, etiology and treatment modalities of molar-incisor hypomineralization (MIH) among Egyptian fifth year dental students, general dental practitioners and dental specialists.~There were two routes for delivering the questionnaire either as online questionnaire sent to the participants by email or as a hard copy that is hand delivered.
Study NCT01887197 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Absorptive clearance scan
Description: Subjects inhale a nebulized mixture of the radiopharmaceuticals Indium 111-DTPA and Technetium 99m sulfur colloid.
Study NCT04376892 — intervention group
Intervention type: OTHER
Intervention: Quality of life measurement
Description: Quality of life measurement by St. George Respiratory questionnaire
Study NCT01887197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inhaled hypertonic saline (7%)
Description: nebulized hypertonic saline (7%)
Study NCT01887197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mannitol inhalation powder
Description: mannitol inhalation powder
Study NCT01053949 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pomalidomide
Description: Pomalidomide 4 mg continuous daily oral route on 21 days per 28 days cycle. The proposed dose of dexamethasone is considered standard, 40mg/day once a week.
Study NCT02056951 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Multidisciplinary rehabilitation
Description: Multidisciplinary rehabilitation includes interventions from the physical and psychological dimensions:~* health education~* exercise therapy~* back school~* physical treatments~* psychological interventions in groups and individual counselling~* rehabilitation/social counselling.
Study NCT02056951 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Interprofessional rehabilitation
Description: Interprofessional rehabilitation includes also interventions from the physical and psychological dimensions:~* education about low back pain~* behavioural exercise therapy~* coping with pain~* relaxation~* work related informations
Study NCT01053949 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pomalidomide
Description: Pomalidomide 4 mg continuous daily oral route on 28 days of a 28 days cycle The proposed dose of dexamethasone is considered standard, 40mg/day once a week.
Study NCT03734536 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: REGENETEN™ Bioinductive Implant
Description: The REGENETEN™ Bioinductive Implant is a bioabsorbable device that provides a layer of collagen over injured tendons.
Study NCT03734536 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Arthroscopic repair of the high-grade (>50%) partial-thickness
Description: Surgical treatment of partial-thickness rotator cuff tears using standard techniques.
Study NCT02685852 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exenatide
Description: Exenatide at a dose of 5 mcg
Study NCT02685852 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acarbose
Description: Acarbose at a dose of 25 mg
Study NCT02685852 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acarbose
Description: Acarbose at a dose of 25 mg
Study NCT02685852 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Exenatide Placebo
Description: Placebo for Exenatide
Study NCT02685852 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acarbose Placebo
Description: Placebo for Acarbose
Study NCT02694523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risankizumab
Description: Risankizumab administered by subcutaneous (SC) injection
Study NCT02456116 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: PCA/NSAID
Description: standard boli of morphine by pressing a button of PCA
Study NCT00984802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMX-2043
Description: Solution for IV administration at 0.8, 1.6 or 2.4 mg/kg single dose.
Study NCT00984802 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: Vehicle solution for IV administration single dose.
Study NCT01461863 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Porridge protein calorie supplement
Description: 250 gm of fortified flour to make porridge containing 1062 kcal and 42 gm protein
Study NCT01461863 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: multivitamin
Description: Standard multivitamin
Study NCT03403491 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: patientMpower application
Description: electronic health journal for patient to record weight, blood pressure, medication adherence and symptoms
Study NCT02694523 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: adalimumab
Description: Adalimumab pre-filled syringe, administered by subcutaneous (SC) injection